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1. INTRODUCTION {#ajmga38560-sec-0002}
===============

Myhre syndrome (MIM 139210) is a rare autosomal dominant disorder reported so far in over 60 individuals, mostly males diagnosed in childhood or adolescence (Caputo et al., [2012](#ajmga38560-bib-0003){ref-type="ref"}; Lin et al., [2016](#ajmga38560-bib-0017){ref-type="ref"}). Clinical features of this disorder include poor growth, variable degree of intellectual disability, distinctive dysmorphic features including short palpebral fissures, maxillary hypoplasia, small mouth with thin upper lip and short philtrum, prognathism, and thick skin. Restricted joint mobility and scarring abnormalities are striking features of the disorders (Caputo et al., [2012](#ajmga38560-bib-0003){ref-type="ref"}; Le Goff et al., [2011](#ajmga38560-bib-0016){ref-type="ref"}; Lin et al., [2016](#ajmga38560-bib-0017){ref-type="ref"}). Cardiovascular abnormalities include restrictive cardiomyopathy and pericardial disease although congenital heart defects have also been reported (Lin et al., [2016](#ajmga38560-bib-0017){ref-type="ref"}; Starr et al., [2015](#ajmga38560-bib-0034){ref-type="ref"}). Patients with Myhre syndrome might develop various long‐term and life‐threatening complications including systemic hypertension, cardiomyopathy, pericarditis, laryngo‐tracheal stenosis, and pulmonary insufficiency (Garavelli et al., [2016](#ajmga38560-bib-0011){ref-type="ref"}; Lin et al., [2016](#ajmga38560-bib-0017){ref-type="ref"}; Starr et al., [2015](#ajmga38560-bib-0034){ref-type="ref"}).

Myhre syndrome is caused by recurrent missense heterozygous mutations affecting the Ile500 residue of the *SMAD4* gene that encodes a tumor‐suppressor protein affecting the transforming growth factor β (TGF‐β) signaling pathway (Caputo et al., [2012](#ajmga38560-bib-0003){ref-type="ref"}; Le Goff et al., [2011](#ajmga38560-bib-0016){ref-type="ref"}; Piccolo et al., [2014](#ajmga38560-bib-0026){ref-type="ref"}). A mutation in Arg496 has been described in a minority of patients (Caputo et al., [2014](#ajmga38560-bib-0002){ref-type="ref"}; Michot et al., [2014](#ajmga38560-bib-0020){ref-type="ref"}). We report a 2‐year‐old female child harboring a de novo mutation affecting Ile500 who presented with poor growth, dysmorphic features, corectopia (also known as ectopia pupillae), and tetralogy of Fallot (TOF). This case is remarkable for the early diagnosis and the ocular and cardiac abnormalities which have not been previously reported in individuals with Myhre syndrome.

2. CASE REPORT {#ajmga38560-sec-0003}
==============

The child was born to non‐consanguineous parents by ceasarean section after 38 weeks of gestation complicated by intrauterine growth retardation and a prenatal diagnosis of TOF. Her birth weight was 2.3 kg (3th centile). The diagnosis of classic TOF and right aortic arch was confirmed by echocardiogram at birth. She underwent cardiac catheterizations at 3 and 19 days of life for pulmonary balloon dilation that was only partially successful and was followed by 5 mm coronary stent positioning into the right ventricular outflow tract to increase pulmonary blood flow. An aorta of normal caliber was noted during aortic catheterization. At 7 months of age, she underwent complete repair of the TOF with closure of the ventricular septum defect, trans‐anular pulmonary patch, and left pulmonary artery patch repair. At the age of 2 years and 10 months, she underwent another surgical intervention for correction of right ventricular outflow tract obstruction. At chest re‐opening, a diffusely fibrotic scar tissue around the great vessels, on the epicardium, and on the transanular patch was observed.

At the age of 11 months, she was found to have a tense abdomen and an abdominal ultrasound revealed ascites that resolved within approximately 24 hr following treatment with diuretics and a phosphodiesterase III inhibitor (enoximone). Liver and function tests did not reveal any abnormalities and the cause for the ascites remained unclear.

She had feeding difficulties only in the first months of life. Since birth her growth has been deficient with weight, height, and head circumference all below the 5th centile. She had left esotropia, displacement of the eye pupil from its normal and central position (i.e., corectopia) more evident in the left eye, short palpebral fissures, hypertelorism, flat nasal bridge, highly arched palate, and brachydactyly (Figure [1](#ajmga38560-fig-0001){ref-type="fig"}). Her development was slightly delayed: she was able to sit by 11 months and to walk independently at 20 months. By 16 months of age, she said her first words. At her last evaluation at the age of 23 months, her weight was 8.410 kg (\<5th centile), height 69.2 cm (\<5th centile), and OFC 44.5 cm (\<5th centile). The auditory brain steam response (ABR) was normal and the ophthalmology evaluation did not reveal lens dislocation or retinal abnormalities. The array‐CGH showed microdeletions 3q29 of 54 kb (from nucleotide 195,419,168 to 195,472,855 on human reference genome hg19), 4q13.3 of 120 kb (71,162,798--71,283,216), 7q34 of 65 kb (142,825,843--142,890,668), and 15q14 of 71 kb (34,735,949--34,806,953) and a 7q11.21 microduplication of 194 kb (62,460,665--62,654,363) that were all overlapping with copy number variants detected in controls and thus, they were interpreted as non‐pathogenic.

![(a) Patient facial features at the ages of 6 months and 2 years. (b) Flat nasal bridge, short palpebral fissures, smooth philtrum, thin upper lip can be noted. (c) Corectopia of the left eye. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\].](AJMG-176-426-g001){#ajmga38560-fig-0001}

2.1. Whole exome sequencing {#ajmga38560-sec-0004}
---------------------------

After informed consent, the child was enrolled in the Telethon Undiagnosed Program (TUDP) and underwent whole exome sequencing (WES). A total of 56,434 high‐quality variants were identified in the proband. Of these variants, 50,825 were single nucleotide variants, 5,609 were indels, 10,625 were predicted to impact a protein sequence, and 510 were also rare (frequency \<0.01) according to population database queries. Of these, 14 variants were de novo, 2 were X‐linked, and 461 were homozygous or compound‐heterozygous, considering trio segregation. The subsequent prioritization process was based on the selection of variants with potential loss‐of‐function effect, with higher Combined Annotation Dependent Depletion (CADD) score (Kircher et al., [2014](#ajmga38560-bib-0014){ref-type="ref"}), and involving genes related to the patient phenotype. As top candidate, one de novo (g.chr18:48604676A\>G according to GRCh37) variant in *SMAD4* (NM_005359.5: c.1498A\>G) was identified. This variant causes the p.Ile500Val substitution repeatedly found in Myhre syndrome patients (Caputo et al., [2012](#ajmga38560-bib-0003){ref-type="ref"}; Le Goff et al., [2011](#ajmga38560-bib-0016){ref-type="ref"}). The mutation was confirmed by Sanger sequencing. Both parents did not harbor the mutation. Targeted analysis of the reads corresponding to genes associated to anterior segment dysgenesis (Reis & Semina, [2011](#ajmga38560-bib-0027){ref-type="ref"}) (*COL1A1*, *COL4A*, *B3GALTL*, *BMP4*, *BMP7*, *CYP1B1*, *FOX2C1*, *FOXC2*, *FOXE3*, *JAG1*, *LAMB2*, *PAX6*, *PIK3CA*, *PITX2*, *PITX3*) revealed no variants.

3. DISCUSSION {#ajmga38560-sec-0005}
=============

Previously, the youngest Myhre syndrome patient reported was a 3‐year‐old boy lacking the distinctive findings such as restricted joint movement, compact build and dysmorphic features who was part of a series reporting the results of WES (Need et al., [2012](#ajmga38560-bib-0022){ref-type="ref"}). Early clinical diagnosis of Myhre syndrome in infancy is difficult because several features become evident in late childhood and thus, WES is an effective method for recognition of this disorder.

Ocular involvement with cataracts, strabismus, retinitis pigmentosa, maculopathy, papilledema, and pseudo‐papilledema has been reported in Myhre syndrome (Table [1](#ajmga38560-tbl-0001){ref-type="table-wrap"}). However, corectopia has not yet been reported. The lack of variants in known genes associated with anterior segment dysgenesis suggests that the *SMAD4* mutation is responsible for the corectopia. Corectopia is generally associated with lens dislocation (Colley et al., [1991](#ajmga38560-bib-0007){ref-type="ref"}), but the child we report herein presented with corectopia without lens dislocation. Although it has not been reported so far in Myhre patients, corectopia with or without lens dislocation has been described in other connective tissue disorders including Marfan syndrome, Weill‐Marchesani syndrome (Colley et al., [1991](#ajmga38560-bib-0007){ref-type="ref"}), and *ADAMTSL4‐*related disorder (Chandra et al., [2012](#ajmga38560-bib-0004){ref-type="ref"}; Christensen et al., [2010](#ajmga38560-bib-0006){ref-type="ref"}; Sharifi, Tjon‐Fo‐Sang, Cruysberg, & Maat‐Kievit, [2013](#ajmga38560-bib-0030){ref-type="ref"}), which are all characterized by defects of TGF‐β pathway (Table [2](#ajmga38560-tbl-0002){ref-type="table-wrap"}). Moreover, corectopia has been reported in *Fbn2* and *Adamtsl4* null mice showing disruption of extracellular microfibril biogenesis (Collin et al., [2015](#ajmga38560-bib-0008){ref-type="ref"}; Shi, Tu, Mecham, & Bassnett, [2013](#ajmga38560-bib-0031){ref-type="ref"}).

###### 

Summary of the ocular findings reported in patients with Myhre syndrome carrying *SMAD4* mutation

  Oncular finding                        Number of patient with abnormality/total number of patients[^a^](#ajmga38560-note-0001){ref-type="fn"}
  -------------------------------------- --------------------------------------------------------------------------------------------------------
  Anterior segment defects               
  Corectopia                             1/56 (2%)
  Refractory abnormality                 18/56 (32%)
  Strabismus                             13/56 (23%)
  Cataract                               6/56 (11%)
  Posterior segment defects              
  Pseudopapillema                        3/56 (5%)
  Papilledema                            1/56 (2%)
  Retinitis pigmentosa and maculopathy   2/56 (4%)

Include 53 cases of the literature reviewed by Lin et al. ([2016](#ajmga38560-bib-0017){ref-type="ref"}), the additional cases by Erdem, Sahin, and Tatar ([2017](#ajmga38560-bib-0010){ref-type="ref"}) and Garavelli et al. ([2016](#ajmga38560-bib-0011){ref-type="ref"}) published after Lin et al. ([2016](#ajmga38560-bib-0017){ref-type="ref"}), and the current case.
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###### 

Genetic disorders with corectopia and/or lens dislocation

  Condition                                                 Ectopia lens   Corectopia   Gene defect                                                                           Reference
  --------------------------------------------------------- -------------- ------------ ------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ocular disorders                                                                                                                                                            
  Familial ectopia lentis                                   \+             −            *FBN1*                                                                                Zhang, Lai, Capasso, Han, and Levin ([2015](#ajmga38560-bib-0039){ref-type="ref"})
  Rieger anomaly and other anterior segment dysgenesis      −              \+           *PAX6*, *PITX2*, *JAG1 FOXC1*, *COL4A1*, *PITX3*, *BMP4*, *FOXC2*, *FOXE3*, *PRDM5*   Cheong et al. ([2016](#ajmga38560-bib-0005){ref-type="ref"}); Micheal et al. ([2016](#ajmga38560-bib-0019){ref-type="ref"}); Reis et al. ([2011](#ajmga38560-bib-0028){ref-type="ref"}); Reis and Semina ([2011](#ajmga38560-bib-0027){ref-type="ref"}); Tümer and Bach‐Holm ([2009](#ajmga38560-bib-0035){ref-type="ref"}); Verdin et al. ([2014](#ajmga38560-bib-0038){ref-type="ref"})
  Connective tissue disorders                                                                                                                                                 
  Marfan syndrome                                           \+             −            *FBN1*                                                                                Latasiewicz, Fontecilla, Millá, and Sánchez ([2016](#ajmga38560-bib-0015){ref-type="ref"})
  Beals syndrome                                            \+             −            *FBN2*                                                                                Viljoen ([1994](#ajmga38560-bib-0037){ref-type="ref"})
  Ehlers--Danlos syndrome                                   \+             −            *COL5A1*, *COL5A2*, *COL1A1*                                                          Colley, Lloyd, Ridgway, and Donnai ([1991](#ajmga38560-bib-0007){ref-type="ref"}); Sadiq and Vanderveen ([2013](#ajmga38560-bib-0029){ref-type="ref"})
  ADAMTSL4‐related disorders                                \+             −            *ADAMTSL4*                                                                            Christensen, Fiskerstrand, Knappskog, Boman, and Rødahl ([2010](#ajmga38560-bib-0006){ref-type="ref"}); Overwater et al. ([2017](#ajmga38560-bib-0023){ref-type="ref"})
  Weill--Marchesani syndrome                                \+             \+           *ADAMTS10*, *ADAMTS17*, *LTBP2*                                                       Sadiq and Vanderveen ([2013](#ajmga38560-bib-0029){ref-type="ref"})
  Knobloch syndrome                                         \+             −            *COL18A1*, *ADAMTS18*                                                                 Khan et al. ([2012](#ajmga38560-bib-0013){ref-type="ref"})
  Inborn errors of metabolism                                                                                                                                                 
  Homocystinuria                                            \+             −            *CBS*                                                                                 Burke, O\'Keefe, Bowell, and Naughten ([1989](#ajmga38560-bib-0001){ref-type="ref"})
  Sulfite oxidase deficiency                                \+             −            *SUOX*                                                                                Shih et al. [1977](#ajmga38560-bib-0033){ref-type="ref"}
  Molybdenum cofactor deficiency                            \+             −            *MOCS1*                                                                               Lueder and Steiner ([1995](#ajmga38560-bib-0018){ref-type="ref"})
  Multiple congenital anomalies/malformation syndromes                                                                                                                        
  Sturge--Weber syndrome                                    \+             \+           *GNAQ*                                                                                Moore, Reck, and Chen ([2011](#ajmga38560-bib-0021){ref-type="ref"}); Shields et al. ([2015](#ajmga38560-bib-0032){ref-type="ref"})
  Traboulsi syndrome                                        \+             −            *ASPH*                                                                                Patel et al. ([2014](#ajmga38560-bib-0024){ref-type="ref"})
  Spondylometaphyseal dysplasia with cone‐rod dystrophy     \+             \+           *PCYT1A*                                                                              Yamamoto et al. ([2014](#ajmga38560-bib-0036){ref-type="ref"})
  Stromme syndrome                                          −              \+           *CENPF*                                                                               Keegan et al. ([2004](#ajmga38560-bib-0012){ref-type="ref"})
  Microphthalmia/coloboma and skeletal dysplasia syndrome   −              \+           *MAB21L2*                                                                             Deml et al. ([2015](#ajmga38560-bib-0009){ref-type="ref"})

© 2018 Wiley Periodicals, Inc.

Cardiovascular anomalies have been reported in approximately 70% of patients with Myhre syndrome (Lin et al., [2016](#ajmga38560-bib-0017){ref-type="ref"}). The most frequent congenital heart defects are large patent ductus arteriosus, atrial and ventricular septal defects, and stenosis of aortic and mitral valves (Lin et al., [2016](#ajmga38560-bib-0017){ref-type="ref"}). Among these defects, TOF has not been reported. Moreover, patients with Myhre syndrome can develop recurrent pericardial effusion, constrictive pericarditis and cardiomyopathy (Lin et al., [2016](#ajmga38560-bib-0017){ref-type="ref"}; Picco et al., [2013](#ajmga38560-bib-0025){ref-type="ref"}). Given the occurrence of such complications, a timely diagnosis of Myhre syndrome is important.

In conclusion, we report a young child with Myhre syndrome due to *SMAD4* mutation that presented corectopia and TOF, two features that have not been previously reported in Myhre syndrome patients.
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